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A key challenge in human medical genetics is 
developing the ability to suppress the expression 
of mutant genes that cause diseases that are 
transmitted as dominant traits. This is particu-
larly true for the neurodegenerative disorders; 
many such disorders have dominantly inherited 
genetic forms and are not reversible with current 
therapies. One example is amyotrophic lateral 
sclerosis (ALS): approximately 15% of cases can 
currently be attributed to dominant, high-pene-
trance gene variants,1 and many more ALS-causing 
genes probably remain to be discovered.
There are four approaches to suppressing the 
toxic effects of etiologic genes: the use of micro-
RNA or antisense oligonucleotides (ASOs; com-
plementary DNA or RNA sequences designed to 
pair with the target sequence and activate RNA 
degradation) for ablation of the RNA transcribed 
from the gene, reduction of the burden of the 
mutant protein (e.g., immune-mediated reduction), 
interference with the transcriptional process with 
the use of small molecules, and somatic-cell 
mutagenesis — that is, back-mutating the gene 
in the appropriate nongermline cells to its wild-
type form (Fig. 1). Several reports have docu-
mented that the first three of these methods are 
feasible. The great advantage of the last ap-
proach is that correction of the mutant DNA 
eliminates downstream abnormalities and is at 
least in theory a one-time intervention.
However, somatic-cell mutagenesis has been 
elusive. Methods involving the use of specialized 
enzymes (e.g., zinc-finger nucleases) that are 
targeted to specific regions of DNA have proved 
to be inefficient. Particularly exciting, therefore, 
is the debut of methods that are based on enzy-
matic clustered regularly interspaced short pal-
indromic repeats (CRISPR)–Cas9 gene editing.3,4 
CRISPR-Cas9, together with a single guide RNA 
(sgRNA), makes up a complex that targets a spe-
cific gene sequence — complementary to part of 
the sgRNA — for precise gene editing and cor-
rection. The challenge is delivering this editing 
system in vivo.
A study recently reported by Gaj and col-
leagues involved use of adeno-associated virus 9 
(AAV9) to deliver CRISPR-Cas9 to transgenic 
mice that carried multiple copies of a human 
mutant SOD1 (in which glycine is replaced by 
alanine at position 93).2 ALS develops in these 
Figure 1 (facing page). Four Ways to Suppress Gene 
 Expression.
There are four approaches to suppressing the toxic 
 effects of a mutated gene: ablation of RNA, immune 
reduction of protein, transcriptional interference with 
small molecules, and DNA mutagenesis. In target RNA 
ablation, sequence‑specific pre‑microRNA (pre‑miRNA), 
which is encoded in the nucleus and sent to the cyto‑
plasm, or externally introduced pre‑miRNA or double‑
stranded RNA (dsRNA) is cleaved by the Dicer protein 
into 21‑bp sequences; these sequences can be incorpo‑
rated into the RNA‑induced silencing complex (RISC). 
RISC then binds to the target sequence and ablates or 
represses it. RNA degradation can also be achieved by 
delivering single‑stranded, modified DNA that targets 
the messenger RNA (mRNA); RNAse H then recogniz‑
es and degrades the RNA target. Immune reduction 
depends on antibodies that are directed toward the 
pathogenic protein. In transcriptional interference with 
small molecules, drugs that block enhancers or activa‑
tors of transcription are used to reduce or prevent pro‑
tein production. CRISPR‑Cas9 mutates DNA by cutting 
through double‑stranded DNA at a specific gene se‑
quence, to which it is directed by a single guide RNA 
(sgRNA). After the cut is made, the DNA‑repair machin‑
ery of the cell automatically tries to fix it, and it is at this 
juncture that different types of edits (e.g., deletions) can 
be introduced at the cleavage site. Gaj et al.2 designed 
a CRISPR‑Cas9 system to disrupt expression of human 
SOD1 in a transgenic mouse model of amyotrophic lat‑
eral sclerosis; they packaged the CRISPR‑Cas9 system 
into a virus vector and injected it into the facial veins 
of affected mice, after which levels of mutant protein 
declined in the lumbar and thoracic spines and the 
 onset of disease was delayed. The abbreviation siRNA 
denotes small interfering RNA.
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mice at approximately 90 days after birth, and 
the mice die at approximately 125 days. Within 
a day after the mice were born, Gaj et al. injected 
them through the facial vein with an AAV9 con-
taining CRISPR-Cas9 and an sgRNA designed to 
disrupt SOD1, and systemic delivery was achieved. 
They detected a reduction in levels of mutant 
SOD1 protein in the lumbar spine and in the 
thoracic spine to 30% and 39%, respectively, of 
levels in untreated mice, with a 37% delay in 
disease onset (from a mean of 92 days after birth 
to a mean of 126 days). Although the rate of 
disease progression did not slow, the delay in 
onset prolonged overall survival by 25%. A dis-
advantage of this approach is that the activity of 
CRISPR-Cas9 is ongoing, which increases the 
risk of off-target effects, although these were 
minimal in the Gaj et al. study.
Several hurdles lie in the path between this 
proof-of-principle study in mice and the treat-
ment of humans who have ALS. A key consid-
eration is the timing of treatment. Gaj and 
colleagues delivered the gene-editing system 
immediately after birth, when the blood–brain 
barrier is most permeable, and before the dis-
ease was active. Although screening in utero for 
mutations in families with ALS might be possi-
ble, this would preclude treatment for people 
who have a genetic cause of ALS but do not have 
a family history; such cases are detectable only 
through population-level screening. The alterna-
tive is treatment after disease onset, but it is not 
clear whether that would be effective. Another 
consideration is that the gene-editing system 
used by Gaj et al. reduces the expression of both 
wild-type and mutant SOD1 but is beneficial be-
cause insufficiency of wild-type SOD1 protein is 
not harmful. A benefit of this strategy is that 
one therapy can be used for any mutant SOD1. 
However, for other genes, an insufficiency of the 
wild-type protein could turn out to be patho-
genic, in which case a strategy that targets only 
the mutated gene would be required. In that 
situation, since most variants causing ALS are 
rare, the paucity of persons harboring these vari-
ants would represent a challenge in clinical trial 
enrollment. As with other innovative therapies, 
another potential hurdle is the securing of regu-
latory approval.
There is evidence that the CRISPR-Cas9 ap-
proach is effective against structural changes to 
the genome, such as variations in the copy num-
ber of a gene; indeed, the mouse model in the 
Gaj et al. study harbors multiple copies of the 
transgene. In this regard, it is relevant that 
CRISPR-Cas9 inactivates multiple copies of por-
cine endogenous retrovirus in a kidney epithelial 
cell line. However, it is difficult to know wheth-
er treatment would be effective for common gene 
variations that have a small effect on risk or for 
the 1% of people with two rare variants underly-
ing their ALS.5 A final point is that it would also 
be instructive to inactivate variants that shorten 
survival (as opposed to increasing susceptibility): 
such a strategy could be effective in treating 
people after the onset of disease.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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